The article linked below points to an idea that seems fundemental to myeloma care.  Can anyone explain why oncs don't take cost and possible side effects into their thinking when prescribing a course of therapy for a myeloma patient?!  David 

"Some add only a few weeks of survival at a cost of tens of thousands of
dollars. It is important for oncologists and other members of the
cancer community to understand how economic evaluations of cancer
interventions are performed and to use and critique these evaluations,
according to an article that appears in the July/August issue of CA: A Cancer Journal for Clinicians."

http://www.medscape.com/v...